ivaltinostat oral (CG-750) / CG Invites - LARVOL DELTA

Crystal Genomics receives approval for phase 1 clinical trial as a new drug candidate for fibrosis [Google translation] (Hankyung) - "...the Ministry of Food and Drug Safety approved a phase 1 clinical trial to evaluate pharmacokinetic and pharmacodynamic characteristics, safety and tolerability by oral administration of CG-750 to healthy men the day before."

New P1 trial • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Crystal Genomics, applied for the first phase of fibrosis treatment ’CG-750’ in Korea [Google translation] (Hankyung) - "Crystal Genomics...announced on the 21st that it applied for a phase 1 clinical trial of 'CG-750', a new drug candidate for fibrosis treatment, to the Ministry of Food and Drug Safety....Phase 1 of the clinical trial is a multiple dose escalation test (MAD), which is conducted in 24 healthy adult males at Seoul National University Hospital. Pharmacokinetics, safety, and tolerability are evaluated by repeatedly administering the pill (capsule) formulation of CG-750....In particular, the development of oral formulations is expected to increase patient convenience and reduce the economic burden."

New P1 trial • Idiopathic Pulmonary Fibrosis